| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/ONC.2017.269 |
| P698 | PubMed publication ID | 28783166 |
| P50 | author | Fabio Casciano | Q50149058 |
| Giandomenico Russo | Q55445103 | ||
| Paola Guerriero | Q57027532 | ||
| George A. Calin | Q64785850 | ||
| P2093 | author name string | X Huang | |
| C M Croce | |||
| G Zauli | |||
| P Secchiero | |||
| G Marcucci | |||
| F Malavasi | |||
| M Negrini | |||
| L J Lee | |||
| E Saccenti | |||
| A Bresin | |||
| S Sabbioni | |||
| E Callegari | |||
| A Chillemi | |||
| B K Elamin | |||
| E M A A Hussein | |||
| L D'Abundo | |||
| P2860 | cites work | miR-15 and miR-16 induce apoptosis by targeting BCL2 | Q24536069 |
| Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia | Q24539231 | ||
| MicroRNA-26a/b and their host genes cooperate to inhibit the G1/S transition by activating the pRb protein | Q24601263 | ||
| MicroRNAs in mouse models of lymphoid malignancies | Q24618980 | ||
| MicroRNA expression, survival, and response to interferon in liver cancer | Q24647241 | ||
| Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder | Q24649158 | ||
| Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model | Q24655262 | ||
| The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo | Q24657924 | ||
| TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemia | Q26773053 | ||
| Anti-CD38 antibody therapy: windows of opportunity yielded by the functional characteristics of the target molecule | Q27015933 | ||
| Anti-tumor activity of a miR-199-dependent oncolytic adenovirus | Q27307206 | ||
| Silencing of microRNAs in vivo with 'antagomirs' | Q27860891 | ||
| Genomic aberrations and survival in chronic lymphocytic leukemia | Q28141442 | ||
| Chronic lymphocytic leukemia | Q28236621 | ||
| MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia | Q28241703 | ||
| The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia | Q28269786 | ||
| A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia | Q28279141 | ||
| Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology | Q28287124 | ||
| MYC stimulates EZH2 expression by repression of its negative regulator miR-26a | Q28291303 | ||
| MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia | Q28304835 | ||
| A microRNA component of the p53 tumour suppressor network | Q28305330 | ||
| Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness | Q29013141 | ||
| LNA-mediated microRNA silencing in non-human primates | Q29615962 | ||
| Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice | Q29619279 | ||
| Integrative genome analysis reveals an oncomir/oncogene cluster regulating glioblastoma survivorship | Q33719798 | ||
| Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia | Q33873337 | ||
| Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups | Q33913537 | ||
| Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression | Q34068006 | ||
| miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222 | Q34195513 | ||
| A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis | Q34282319 | ||
| The oncogenic role of miR-155 in breast cancer | Q34284424 | ||
| The oncogenic role of microRNA-130a/301a/454 in human colorectal cancer via targeting Smad4 expression | Q34326881 | ||
| Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia | Q34504188 | ||
| Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era | Q34568868 | ||
| MicroRNAs in human cancer: from research to therapy | Q34630207 | ||
| MiR-26a inhibits proliferation and migration of breast cancer through repression of MCL-1 | Q34764211 | ||
| MicroRNAs in normal and malignant hematopoiesis | Q34785149 | ||
| B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia | Q34830865 | ||
| In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma | Q35108549 | ||
| MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin-6-Stat3 pathway | Q46255425 | ||
| Mouse models in the study of chronic lymphocytic leukemia pathogenesis and therapy | Q46868785 | ||
| Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities | Q47420573 | ||
| Functional studies of miR-130a on the inhibitory pathways of apoptosis in patients with chronic myeloid leukemia. | Q50240916 | ||
| The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting. | Q53271932 | ||
| Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. | Q53572738 | ||
| MicroRNA-130a is down-regulated in hepatocellular carcinoma and associates with poor prognosis. | Q54191926 | ||
| microRNAome Expression in Chronic Lymphocytic Leukemia: Comparison with Normal B-cell Subsets and Correlations with Prognostic and Clinical Parameters | Q56097570 | ||
| LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas | Q61640851 | ||
| Primary body cavity-based AIDS-related lymphomas | Q71015787 | ||
| ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile | Q73023141 | ||
| CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia | Q74064365 | ||
| Purification of clinical-grade monoclonal antibodies by chromatographic methods | Q81009667 | ||
| MicroRNA-130a inhibits cell proliferation, invasion and migration in human breast cancer by targeting the RAB5A. | Q35144855 | ||
| miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia | Q35220412 | ||
| Primary follicular lymphoma of the small intestine: alpha4beta7 expression and immunoglobulin configuration suggest an origin from local antigen-experienced B cells | Q35748903 | ||
| Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia | Q35849945 | ||
| A miR-130a-YAP positive feedback loop promotes organ size and tumorigenesis. | Q36027005 | ||
| Targeting leukemia stem cells in vivo with antagomiR-126 nanoparticles in acute myeloid leukemia | Q36248867 | ||
| Repression of Esophageal Neoplasia and Inflammatory Signaling by Anti-miR-31 Delivery In Vivo | Q36361891 | ||
| B-cell chronic lymphocytic leukemia, a clonal disease of B lymphocytes with receptors that vary in specificity for (auto)antigens | Q36388626 | ||
| Targeting of RUNX3 by miR-130a and miR-495 cooperatively increases cell proliferation and tumor angiogenesis in gastric cancer cells | Q36545132 | ||
| CD38 and chronic lymphocytic leukemia: a decade later | Q36615126 | ||
| The role of microRNA and other non-coding RNA in the pathogenesis of chronic lymphocytic leukemia | Q36914074 | ||
| Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia | Q36948708 | ||
| microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival | Q37027816 | ||
| In vivo delivery of miRNAs for cancer therapy: challenges and strategies. | Q37228217 | ||
| Karyotype-specific microRNA signature in chronic lymphocytic leukemia | Q37412319 | ||
| Progress in microRNA delivery | Q37478933 | ||
| Transferrin-conjugated SNALPs encapsulating 2'-O-methylated miR-34a for the treatment of multiple myeloma. | Q37618873 | ||
| From pathogenesis to treatment of chronic lymphocytic leukaemia | Q37643423 | ||
| Role of microRNA in the pathogenesis of malignant lymphoma. | Q38095676 | ||
| Therapeutic targeting of microRNAs: current status and future challenges | Q38228101 | ||
| Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. | Q38657175 | ||
| MicroRNA-130a promotes the metastasis and epithelial-mesenchymal transition of osteosarcoma by targeting PTEN. | Q38781836 | ||
| miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the Eµ-TCL1 mouse model. | Q38862227 | ||
| miR-130a activates apoptotic signaling through activation of caspase-8 in taxane-resistant prostate cancer cells. | Q38864099 | ||
| MicroRNA-130a associates with ribosomal protein L11 to suppress c-Myc expression in response to UV irradiation | Q38924922 | ||
| Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia | Q39181050 | ||
| MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma | Q39385197 | ||
| miRNA-130a targets ATG2B and DICER1 to inhibit autophagy and trigger killing of chronic lymphocytic leukemia cells | Q39393408 | ||
| Lentivirus-mediated overexpression of microRNA-199a inhibits cell proliferation of human hepatocellular carcinoma | Q39489279 | ||
| Regulated and multiple miRNA and siRNA delivery into primary cells by a lentiviral platform | Q39508077 | ||
| Mutations driving CLL and their evolution in progression and relapse | Q39714436 | ||
| Quantification of circulating miRNAs by droplet digital PCR: comparison of EvaGreen- and TaqMan-based chemistries. | Q40241153 | ||
| miR-130a acts as a potential diagnostic biomarker and promotes gastric cancer migration, invasion and proliferation by targeting RUNX3. | Q41621654 | ||
| Regulation of angiogenesis through the efficient delivery of microRNAs into endothelial cells using polyamine-coated carbon nanotubes | Q42229292 | ||
| CD5+CD23+ leukemic cell populations in TCL1 transgenic mice show significantly increased proliferation and Akt phosphorylation | Q43091453 | ||
| A gold nanoparticle platform for the delivery of functional microRNAs into cancer cells | Q44194580 | ||
| P433 | issue | 47 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | microRNA | Q310899 |
| lymphocyte | Q715347 | ||
| chronic lymphocytic leukemia | Q1088156 | ||
| leukemia | Q29496 | ||
| P304 | page(s) | 6617-6626 | |
| P577 | publication date | 2017-08-07 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | Anti-leukemic activity of microRNA-26a in a chronic lymphocytic leukemia mouse model | |
| P478 | volume | 36 |
| Q90469311 | Targeting of CD38 by the tumor suppressor miR-26a serves as a novel potential therapeutic agent in multiple myeloma |
| Q46252865 | The Potential of Zebrafish as a Model Organism for Improving the Translation of Genetic Anticancer Nanomedicines |
| Q90394311 | Tumor Suppressors in Chronic Lymphocytic Leukemia: From Lost Partners to Active Targets |
| Q91610547 | miRNA-26a-5p Accelerates Healing via Downregulation of PTEN in Fracture Patients with Traumatic Brain Injury |
| Q58580483 | miRNAs involvement in the pathogenesis of Richter's syndrome |
Search more.